Assertio Holdings (ASRT) Appoints Mark Reisenauer to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
- Moderna stock rises on latest cancer vaccine data publication
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors
December 17, 2024 8:30 AM ESTLAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (Assertio or the Company) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an independent director to the Companys Board of Directors. Mr. Reisenauer will serve as a member of the Compensation Committee.
Mark is a highly accomplished commercial leader in complex, competitive therapeutic areas who also brings extensive oncology and hematology product experience to our board, said Heather Mason, Chair of Assertio. His successful new product and... More



